Product Description
IGF-1 LR3 + MOTS-C (1mg/10mg)
Advanced Performance, Recovery, and Metabolic Support Formula
Prescription only - Requires provider consultation
Description
The IGF-1 LR3 + MOTS-C blend is a prescription combination designed for clinically guided use. This advanced formulation pairs two highly studied peptides that target performance, cellular energy, and tissue repair from different angles. IGF-1 LR3 supports muscular adaptation and recovery pathways, while MOTS-C enhances mitochondrial efficiency and metabolic resilience. Together, they provide a dual-action approach for athletes and active individuals seeking improved training output, faster recovery, and support for overall cellular function.
How It Works
• IGF-1 LR3 (1mg)
A longer-acting analog of insulin-like growth factor-1 that supports muscle protein synthesis, satellite cell activation, and recovery signaling. Studies show IGF-1 pathways play an essential role in skeletal muscle hypertrophy, tendon repair, and training adaptation (Yakar et al., 2010; Shavlakadze et al., 2010). This prescription peptide uses the LR3 modification to avoid rapid binding and breakdown, allowing for prolonged receptor activity.
• MOTS-C (10mg)
A mitochondrial-derived prescription peptide shown to regulate energy metabolism, enhance AMPK activation, and improve exercise tolerance. Research demonstrates MOTS-C increases glucose utilization, improves insulin sensitivity, and supports metabolic balance during physical stress (Lee et al., 2015; Reynolds et al., 2021). Its mitochondrial effects make it valuable for individuals experiencing fatigue, slow recovery, or metabolic plateaus.
Benefits
• Supports lean muscle adaptation and recovery
• Enhances mitochondrial energy output
• Promotes improved training endurance and capacity
• Assists in repairing soft tissue after high-stress activity
• Supports healthy metabolic and glucose regulation
• Complements performance, hypertrophy, and cutting protocols
Who This Is For
This prescription blend is commonly used by:
• Athletes seeking improved power, recovery, or conditioning
• Individuals experiencing chronic fatigue or poor recovery
• Those in caloric deficit or cutting phases seeking to maintain output
• People looking to optimize mitochondrial function and cellular energy
Suggested Use
This is a prescription-based peptide and should be used only as directed under medical supervision. Typical courses include 8–12 week performance or recovery cycles as clinically appropriate.
Safety & Research
• IGF-1 LR3 has been studied extensively for musculoskeletal repair and anabolic signaling.
• MOTS-C research demonstrates strong safety and metabolic benefits in both animal and human models.
• No known significant adverse interactions when used under medically supervised dosing ranges.
Key Studies
• Yakar et al., Endocrine Reviews, 2010 – IGF-1 in muscle hypertrophy and recovery
• Shavlakadze et al., Journal of Physiology, 2010 – IGF-1 signaling in tissue repair
• Lee et al., Cell Metabolism, 2015 – Discovery of MOTS-C and its metabolic effects
• Reynolds et al., Aging Cell, 2021 – Human data on MOTS-C improving exercise capacity
Directions For Use
IGF-1 LR3 + MOTS-C (1mg/10mg)
Advanced Performance, Recovery, and Metabolic Support Formula
Prescription only - Requires provider consultation
Description
The IGF-1 LR3 + MOTS-C blend is a prescription combination designed for clinically guided use. This advanced formulation pairs two highly studied peptides that target performance, cellular energy, and tissue repair from different angles. IGF-1 LR3 supports muscular adaptation and recovery pathways, while MOTS-C enhances mitochondrial efficiency and metabolic resilience. Together, they provide a dual-action approach for athletes and active individuals seeking improved training output, faster recovery, and support for overall cellular function.
How It Works
• IGF-1 LR3 (1mg)
A longer-acting analog of insulin-like growth factor-1 that supports muscle protein synthesis, satellite cell activation, and recovery signaling. Studies show IGF-1 pathways play an essential role in skeletal muscle hypertrophy, tendon repair, and training adaptation (Yakar et al., 2010; Shavlakadze et al., 2010). This prescription peptide uses the LR3 modification to avoid rapid binding and breakdown, allowing for prolonged receptor activity.
• MOTS-C (10mg)
A mitochondrial-derived prescription peptide shown to regulate energy metabolism, enhance AMPK activation, and improve exercise tolerance. Research demonstrates MOTS-C increases glucose utilization, improves insulin sensitivity, and supports metabolic balance during physical stress (Lee et al., 2015; Reynolds et al., 2021). Its mitochondrial effects make it valuable for individuals experiencing fatigue, slow recovery, or metabolic plateaus.
Benefits
• Supports lean muscle adaptation and recovery
• Enhances mitochondrial energy output
• Promotes improved training endurance and capacity
• Assists in repairing soft tissue after high-stress activity
• Supports healthy metabolic and glucose regulation
• Complements performance, hypertrophy, and cutting protocols
Who This Is For
This prescription blend is commonly used by:
• Athletes seeking improved power, recovery, or conditioning
• Individuals experiencing chronic fatigue or poor recovery
• Those in caloric deficit or cutting phases seeking to maintain output
• People looking to optimize mitochondrial function and cellular energy
Suggested Use
This is a prescription-based peptide and should be used only as directed under medical supervision. Typical courses include 8–12 week performance or recovery cycles as clinically appropriate.
Safety & Research
• IGF-1 LR3 has been studied extensively for musculoskeletal repair and anabolic signaling.
• MOTS-C research demonstrates strong safety and metabolic benefits in both animal and human models.
• No known significant adverse interactions when used under medically supervised dosing ranges.
Key Studies
• Yakar et al., Endocrine Reviews, 2010 – IGF-1 in muscle hypertrophy and recovery
• Shavlakadze et al., Journal of Physiology, 2010 – IGF-1 signaling in tissue repair
• Lee et al., Cell Metabolism, 2015 – Discovery of MOTS-C and its metabolic effects
• Reynolds et al., Aging Cell, 2021 – Human data on MOTS-C improving exercise capacity
Ingredients
IGF-1 LR3 + MOTS-C (1mg/10mg)
Advanced Performance, Recovery, and Metabolic Support Formula
Prescription only - Requires provider consultation
Description
The IGF-1 LR3 + MOTS-C blend is a prescription combination designed for clinically guided use. This advanced formulation pairs two highly studied peptides that target performance, cellular energy, and tissue repair from different angles. IGF-1 LR3 supports muscular adaptation and recovery pathways, while MOTS-C enhances mitochondrial efficiency and metabolic resilience. Together, they provide a dual-action approach for athletes and active individuals seeking improved training output, faster recovery, and support for overall cellular function.
How It Works
• IGF-1 LR3 (1mg)
A longer-acting analog of insulin-like growth factor-1 that supports muscle protein synthesis, satellite cell activation, and recovery signaling. Studies show IGF-1 pathways play an essential role in skeletal muscle hypertrophy, tendon repair, and training adaptation (Yakar et al., 2010; Shavlakadze et al., 2010). This prescription peptide uses the LR3 modification to avoid rapid binding and breakdown, allowing for prolonged receptor activity.
• MOTS-C (10mg)
A mitochondrial-derived prescription peptide shown to regulate energy metabolism, enhance AMPK activation, and improve exercise tolerance. Research demonstrates MOTS-C increases glucose utilization, improves insulin sensitivity, and supports metabolic balance during physical stress (Lee et al., 2015; Reynolds et al., 2021). Its mitochondrial effects make it valuable for individuals experiencing fatigue, slow recovery, or metabolic plateaus.
Benefits
• Supports lean muscle adaptation and recovery
• Enhances mitochondrial energy output
• Promotes improved training endurance and capacity
• Assists in repairing soft tissue after high-stress activity
• Supports healthy metabolic and glucose regulation
• Complements performance, hypertrophy, and cutting protocols
Who This Is For
This prescription blend is commonly used by:
• Athletes seeking improved power, recovery, or conditioning
• Individuals experiencing chronic fatigue or poor recovery
• Those in caloric deficit or cutting phases seeking to maintain output
• People looking to optimize mitochondrial function and cellular energy
Suggested Use
This is a prescription-based peptide and should be used only as directed under medical supervision. Typical courses include 8–12 week performance or recovery cycles as clinically appropriate.
Safety & Research
• IGF-1 LR3 has been studied extensively for musculoskeletal repair and anabolic signaling.
• MOTS-C research demonstrates strong safety and metabolic benefits in both animal and human models.
• No known significant adverse interactions when used under medically supervised dosing ranges.
Key Studies
• Yakar et al., Endocrine Reviews, 2010 – IGF-1 in muscle hypertrophy and recovery
• Shavlakadze et al., Journal of Physiology, 2010 – IGF-1 signaling in tissue repair
• Lee et al., Cell Metabolism, 2015 – Discovery of MOTS-C and its metabolic effects
• Reynolds et al., Aging Cell, 2021 – Human data on MOTS-C improving exercise capacity
Disclaimer
IGF-1 LR3 + MOTS-C (1mg/10mg)
Advanced Performance, Recovery, and Metabolic Support Formula
Prescription only - Requires provider consultation
Description
The IGF-1 LR3 + MOTS-C blend is a prescription combination designed for clinically guided use. This advanced formulation pairs two highly studied peptides that target performance, cellular energy, and tissue repair from different angles. IGF-1 LR3 supports muscular adaptation and recovery pathways, while MOTS-C enhances mitochondrial efficiency and metabolic resilience. Together, they provide a dual-action approach for athletes and active individuals seeking improved training output, faster recovery, and support for overall cellular function.
How It Works
• IGF-1 LR3 (1mg)
A longer-acting analog of insulin-like growth factor-1 that supports muscle protein synthesis, satellite cell activation, and recovery signaling. Studies show IGF-1 pathways play an essential role in skeletal muscle hypertrophy, tendon repair, and training adaptation (Yakar et al., 2010; Shavlakadze et al., 2010). This prescription peptide uses the LR3 modification to avoid rapid binding and breakdown, allowing for prolonged receptor activity.
• MOTS-C (10mg)
A mitochondrial-derived prescription peptide shown to regulate energy metabolism, enhance AMPK activation, and improve exercise tolerance. Research demonstrates MOTS-C increases glucose utilization, improves insulin sensitivity, and supports metabolic balance during physical stress (Lee et al., 2015; Reynolds et al., 2021). Its mitochondrial effects make it valuable for individuals experiencing fatigue, slow recovery, or metabolic plateaus.
Benefits
• Supports lean muscle adaptation and recovery
• Enhances mitochondrial energy output
• Promotes improved training endurance and capacity
• Assists in repairing soft tissue after high-stress activity
• Supports healthy metabolic and glucose regulation
• Complements performance, hypertrophy, and cutting protocols
Who This Is For
This prescription blend is commonly used by:
• Athletes seeking improved power, recovery, or conditioning
• Individuals experiencing chronic fatigue or poor recovery
• Those in caloric deficit or cutting phases seeking to maintain output
• People looking to optimize mitochondrial function and cellular energy
Suggested Use
This is a prescription-based peptide and should be used only as directed under medical supervision. Typical courses include 8–12 week performance or recovery cycles as clinically appropriate.
Safety & Research
• IGF-1 LR3 has been studied extensively for musculoskeletal repair and anabolic signaling.
• MOTS-C research demonstrates strong safety and metabolic benefits in both animal and human models.
• No known significant adverse interactions when used under medically supervised dosing ranges.
Key Studies
• Yakar et al., Endocrine Reviews, 2010 – IGF-1 in muscle hypertrophy and recovery
• Shavlakadze et al., Journal of Physiology, 2010 – IGF-1 signaling in tissue repair
• Lee et al., Cell Metabolism, 2015 – Discovery of MOTS-C and its metabolic effects
• Reynolds et al., Aging Cell, 2021 – Human data on MOTS-C improving exercise capacity
